NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE: FRX), an international manufacturer and marketer of
pharmaceutical products, will release its Fiscal 2008 Fourth Quarter
financial results before the U.S. stock market opens on Tuesday, April 15,
2008. Later that day, at 10:00 AM EDT, Forest will host a conference call
where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank
Perier, Senior Vice President and Chief Financial Officer, will discuss the
financial results and relevant company and industry topics. The conference
call will be webcast live beginning at 10:00 AM EDT on the Company's
website http://www.frx.com and also on the website http://www.streetevents.com. Please
log on to either website at least fifteen minutes prior to the conference
call as it may be necessary to download software to access the call. A
replay of the conference call will be available until April 30, 2008 at
both websites and also by dialing 1-800-642-1687 (US investors) or
+1-706-645-9291 (international investors), ID 42636974.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
About Forest Laboratories and Its Products
Forest Laboratories is a US-based pharmaceutical company dedicated to
identifying, developing, and delivering products that make a positive
difference in peoples' lives. Forest Laboratories' growing product line
includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults
for the initial and maintenance treatment of major depressive disorder and
generalized anxiety disorder; Namenda(R) (memantine HCl), an
N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment
of moderate to severe Alzheimer's disease; Campral(R)* (acamprosate
calcium), indicated in combination with psychosocial support for the
maintenance of abstinence from alcohol in patients with alcohol dependence
who are abstinent at treatment initiation, and Bystolic(TM) (nebivolol), a
beta-adrenergic receptor blocking agent indicated for the treatment of
hypertension. In addition to our growing product line, Forest also
co-promotes the Daiichi Sankyo, Inc. product Azor(TM)* (amlodipine and
olmesartan medoxomil), a calcium channel blocker and angiotensin receptor
blocker combination product indicated for the treatment of hypertension.
For more information, visit http://www.frx.com.
* Azor is a trademark of Daiichi Sankyo, Inc. and Campral is a registered
trademark of Merck Sante s.a.s., a subsidiary of Merck KGaA, Darmstadt,
Germany.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
CONTACT:
Charles E. Triano, Vice President - Investor
Relations of Forest Laboratories, Inc., +1-212-224-6714,
charles.triano@frx.com
|
